2-(piperidin-3-yl)-3-mercaptopropanoic acid | 607833-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(piperidin-3-yl)-3-mercaptopropanoic acid
• 英文别名: 3-Mercapto-2-(piperidin-3-yl)propanoic acid；2-piperidin-3-yl-3-sulfanylpropanoic acid
• CAS: 607833-57-8
• 化学式: C₈H₁₅NO₂S
• 分子量: 189.279
• InChiKey: ZEKJYPSRDZCIDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  50.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(piperidin-3-yl)-3-mercaptopropanoic acid 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 氯仿 为溶剂， 生成 2-(1-amidinopiperidin-3-yl)-3-mercaptopropanoic acid
  参考文献：
  名称：

  3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (-)2a displays TAFIa IC50 = 3 nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.

  DOI：

  10.1016/j.bmcl.2006.11.078
• 作为产物：
  描述：

  乙基-BOC-3-哌啶-乙酸 在 盐酸 、 ammonium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 2-(piperidin-3-yl)-3-mercaptopropanoic acid
  参考文献：
  名称：

  3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa)

  摘要：

  A novel series of cyclic potent, selective, small molecule, thiol-based inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) and the crystal structures of TAFIa inhibitors bound to porcine pancreatic carboxypeptidase B are described. Three series of cyclic arginine and lysine mimetic inhibitors vary significantly in their selectivity against other human basic carboxypeptidases, carboxypeptidase N and carboxypeptidase B. (-)2a displays TAFIa IC50 = 3 nM and 600-fold selectivity against CPN. Inhibition of TAFIa with (rac)2a resulted in dose dependent acceleration of human plasma clot lysis in vitro and was efficacious as an adjunct to tPA in an in vivo rabbit jugular vein thrombolysis model.

  DOI：

  10.1016/j.bmcl.2006.11.078

文献信息

• Plasma carboxypeptidase b inhibitors
  申请人：Buckman Brad

  公开号：US20060247213A1

  公开（公告）日：2006-11-02

  Compounds of the following formula (I), for example: (1), wherein R 1 , R 2 , R 3 , and R 4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下式子（I）的化合物，例如：（1），其中R1，R2，R3和R4如本文所述，可用作血浆羧肽酶B的抑制剂。本文还描述了含有这些化合物的药物组合物，使用这些化合物作为抗血栓剂的方法以及合成这些化合物的过程。
• PLASMA CARBOXYPEPTIDASE B INHIBITORS
  申请人：BUCKMAN Brad

  公开号：US20090093520A1

  公开（公告）日：2009-04-09

  Compounds of the following formula (I), for example: wherein R 1 , R 2 , R 3 , and R 4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下公式（I）的化合物例如：其中R1，R2，R3和R4的定义如下，可用作血浆羧肽酶B的抑制剂。本文还描述了包含这些化合物的药物组合物，使用这些化合物作为抗血栓剂的方法以及合成这些化合物的过程。
• Plasma Carboxypeptidase B Inhibitors
  申请人：Buckman Brad

  公开号：US20110319366A1

  公开（公告）日：2011-12-29

  Compounds of the following formula (I), for example: wherein R 1 , R 2 , R 3 , and R 4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  以下式(I)的化合物，例如： 其中R1、R2、R3和R4如本文所述，可用作血浆羧肽酶B的抑制剂。本文还描述了含有这些化合物的制药组合物，使用这些化合物作为抗血栓剂的方法以及合成这些化合物的过程。
• Phosphonic acid as Plasma Carboxypeptidase B Inhibitors
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2204373A1

  公开（公告）日：2010-07-07

  Compounds of the following formula (II), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

  例如下式 (II) 的化合物： 其中 R1、R2、R3 和 R4 如本文所述，可用作血浆羧肽酶 B 的抑制剂。本文还描述了含有这些化合物的药物组合物、将这些化合物用作抗血栓剂的方法以及合成这些化合物的工艺。
• TAFI inhibitors and their use to treat pulmonary fibrosis
  申请人：Fujimoto Hajime

  公开号：US20060105995A1

  公开（公告）日：2006-05-18

  The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis.

  本发明涉及 TAFI 抑制剂及其治疗肺纤维化的用途。